Marron Jonathan M, Joffe Steven
Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Blood. 2017 Jul 27;130(4):460-465. doi: 10.1182/blood-2017-01-734558. Epub 2017 Jun 9.
As our technological capacities improve, genomic testing is increasingly integrating into patient care. The field of clinical hematology is no exception. Genomic testing carries great promise, but several ethical issues must be considered whenever such testing is performed. This review addresses these ethical considerations, including issues surrounding informed consent and the uncertainty of the results of genomic testing; the challenge of incidental findings; and possible inequities in access to and benefit from such testing. Genomic testing is likely to transform the practice of both benign and malignant hematology, but clinicians must carefully consider these core ethical issues in order to make the most of this exciting and evolving technology.
随着我们技术能力的提高，基因组检测越来越多地融入患者护理之中。临床血液学领域也不例外。基因组检测前景广阔，但在进行此类检测时必须考虑几个伦理问题。本综述探讨了这些伦理考量，包括围绕知情同意和基因组检测结果不确定性的问题；偶然发现带来的挑战；以及在获取此类检测及其益处方面可能存在的不平等。基因组检测可能会改变良性和恶性血液学的实践，但临床医生必须仔细考虑这些核心伦理问题，以便充分利用这一令人兴奋且不断发展的技术。
